T1 Protein 456 460 body
T2 Organism 248 256 patients
T3 Gene 1862 1880 Anti–PD-1 antibody
T4 Biomarker 1568 1572 PD-1
T5 Condition 1270 1278 melanoma
T7 Protein 1573 1578 PD-L1
T8 Gene 1499 1524 intratumoral PD-1 ligand 
T9 Condition 1071 1097 non–small-cell lung cancer
T10 Organism 1235 1243 patients
T11 Biomarker 1867 1871 PD-1
T12 Biomarker 1512 1516 PD-1
T13 Protein 190 198 antibody
T14 Intervention 808 817 pulmonary
T16 Protein 407 411 body
T18 Organism 1256 1264 patients
T19 Biomarker 224 228 PD-1
T21 Gene 1792 1798  PD-L1
T23 Gene 1511 1517  PD-1 
T24 Protein 194 198 body
T25 Condition 1968 1994 non–small-cell lung cancer
T26 Protein 1793 1798 PD-L1
T27 Organism 1954 1962 patients
T28 Organism 945 953 patients
T29 Condition 1710 1731 PD-L1–negative tumors
T30 Gene 2138 2144  PD-L1
T31 Gene 10 41 Blockade of programmed death 1 
T32 Biomarker 175 185 BMS-936558
T33 Organism 1434 1442 patients
T34 Protein 1568 1578 PD-1–PD-L1
T35 Protein 516 522 8-week
T37 Biomarker 42 46 PD-1
T38 Level 142 151 antitumor
T39 Biomarker 398 402 PD-1
T40 Condition 1099 1107 melanoma
T41 Gene 1709 1715  PD-L1
T42 Condition 1996 2004 melanoma
T43 Organism 1355 1363 patients
T44 Organism 1314 1322 patients
T45 Organism 1680 1688 patients
T46 Protein 2032 2045 adverse-event
T47 Level 85 92 T cells
T49 Protein 1525 1530 PD-L1
T50 Organism 769 777 patients
T52 Organism 1696 1704 patients
T53 Organism 540 548 Patients
T54 Organism 1289 1297 patients
T56 Level 2159 2170 tumor cells
T57 Condition 271 279 melanoma
T58 Organism 1773 1781 patients
T59 Organism 654 662 patients
T60 Protein 393 411 anti–PD-1 antibody
T61 Condition 1328 1345 renal-cell cancer
T62 Condition 1112 1129 renal-cell cancer
T63 Condition 281 307 non–small-cell lung cancer
T64 Organism 1184 1192 patients
